INVESTIGATION/SELECTED PATIENTS--CSSCD-CLINICAL CENTER

研究/选定的患者--CSSCD-临床中心

• 批准号: 3644624
• 负责人: HARVEY DOSIK
• 金额: $ 6.02万
• 依托单位: INTERFAITH MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-11-01 至 1993-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3644624
• 关键词: cooperative study; disease /disorder proneness /risk; human subject; medical complication; newborn human (0-6 weeks); pathology; prognosis; sickle cell anemia; young adult human (21-34)

The Contractor shall serve as a clinical center for the investigation of selected patient groups from the Cooperative Study of Sickle Cell Disease (CSSCD). The Contractor shall collaborate with other CSSCD investigators and NHLBI staff in the development and implementation of a protocol to continue to follow the newborn cohort and patients surviving beyond age thirty-five. The principal objective of this contract is to continue to follow the newborn cohort of patients presently being followed in the CSSCD to better understand severity, onset of early organ damage, and risk factors contributing to certain complications and outcome. This study is also intended to follow another important cohort of patients surviving beyond age thirty-five to better understand longevity and causes of death.

承包商应作为调查的临床中心 镰状细胞疾病合作研究中的精选患者群体 （CSSCD）。 承包商应与其他CSSCD调查人员合作 以及NHLBI的工作人员在制定和实施协议中 继续跟随新生队的队列和年龄超过年龄的患者 三十五。 该合同的主要目标是继续 跟随目前在CSSCD中遵循的新生儿队列 更好地了解严重程度，早期器官损伤的发作和风险 导致某些并发症和结果的因素。 这项研究是 还旨在跟随另一个重要的患者队列 超过35岁以上，可以更好地了解寿命和死亡原因。